Fedratinib in myelofibrosis
A Mullally, J Hood, C Harrison, R Mesa - Blood advances, 2020 - ashpublications.org
Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in
2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to …
2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to …
Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease
Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (TET2) are detected in
peripheral blood cells of a remarkable 5%–10% of adults greater than 65 years of age. They …
peripheral blood cells of a remarkable 5%–10% of adults greater than 65 years of age. They …
Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
CN Harrison, J Nangalia, R Boucher… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …
Reversal of malignant ADAR1 splice isoform switching with Rebecsinib
Adenosine deaminase acting on RNA1 (ADAR1) preserves genomic integrity by preventing
retroviral integration and retrotransposition during stress responses. However, inflammatory …
retroviral integration and retrotransposition during stress responses. However, inflammatory …
Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment
K Hemminki, J Hemminki, A Försti, A Sud - Leukemia, 2023 - nature.com
Studies of survival in hematological malignancies (HMs) have generally shown an
improvement over time, although most of these studies are limited by a short follow-up …
improvement over time, although most of these studies are limited by a short follow-up …
Long‐term pharmacodynamic and clinical effects of twice‐versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin
to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect …
to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect …
Next generation therapeutics for the treatment of myelofibrosis
D Tremblay, J Mascarenhas - Cells, 2021 - mdpi.com
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly,
constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to …
constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to …
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Pre-fibrotic myelofibrosis (pre-PMF) and essential thrombocythemia (ET) are characterized
by similarly increased rate of thrombotic events, but no study specifically analyzed risk …
by similarly increased rate of thrombotic events, but no study specifically analyzed risk …
Current management strategies for polycythemia vera and essential thrombocythemia
P Guglielmelli, AM Vannucchi - Blood Reviews, 2020 - Elsevier
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …